Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients

Pharmacotherapy

Volumn 31, Issue 10, 2011, Pages 934-941

  Spencer, Dustin D ^a   Jacobi, Judith ^a   Juenke, JoEtta M ^b   Fleck, James D ^a   Kays, Michael B ^c  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

Levetiracetam; Neurocritical care; Pharmacokinetics; Seizure prophylaxis

Indexed keywords

ETIRACETAM;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; INTENSIVE CARE; MALE; MONTE CARLO METHOD; NEUROPROTECTION; PROSPECTIVE STUDY; SEIZURE; STEADY STATE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; TANDEM MASS SPECTROMETRY; TERTIARY HEALTH CARE; TRAUMATIC BRAIN INJURY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UNSPECIFIED SIDE EFFECT;

ANTICONVULSANTS; BRAIN INJURIES; CRITICAL CARE; FEMALE; HEMATOMA, SUBDURAL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONTE CARLO METHOD; PIRACETAM; PROSPECTIVE STUDIES; SEIZURES; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME;

EID: 80053303384     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.10.934     Document Type: Article

References (27)

1. UCB, Inc. Keppra (levetiracetam injection for intravenous use) prescribing information. Smyrna, GA; 2008.
2. Betts T, Waegemans T, Crawford P. A multicentre, doubleblind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 2000;9:80-7.
3. Ramael S, Daoust A, Otoul C, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia 2006;47:1128-35. (Pubitemid 44086747)
4. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001;42(suppl 4):24-7. (Pubitemid 32802083)
5. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004;43:707-24. (Pubitemid 39159001)
6. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003;25:347-63. (Pubitemid 36638181)
7. Claassen J, Hirsch LJ, Frontera JA, et al. Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage. Neurocrit Care 2006;4:103-12. (Pubitemid 43793339)
8. Claassen J, Jette N, Chum F, et al. Electrographic seizures and periodic discharges after intracerebral hemorrhage. Neurology 2007;69:1356-65. (Pubitemid 47482450)
9. Szaflarski JP, Rackley AY, Kleindorfer DO, et al. Incidence of seizures in the acute phase of stroke: a population-based study. Epilepsia 2008;49;974-81. (Pubitemid 351795578)
10. Lowenstein DH. Epilepsy after head injury: an overview. Epilepsia 2009;50(suppl 2):4-9.
11. Weisberg LA, Shamsnia M, Elliott D. Seizures caused by nontraumatic parenchymal brain hemorrhages. Neurology 1991;41:1197-9.
12. Vespa PM, O'Phelan K, Shah M, et al. Acute seizures after intracerebral hemorrhage: a factor in progressive midline shift and outcome. Neurology 2003;60:1441-6. (Pubitemid 36554803)
13. Szaflarski P, Meckler JM, Szaflarski M, Shutter LA, Privitera MD, Yates SL. Levetiracetam use in critically ill patients. Neurocrit Care 2007;7:140-7. (Pubitemid 350242663)
14. Ruegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: treatment experience with the first 50 critically ill patients. Epilepsy Behav 2008;12:477-80.
15. Nau KM, Divertie GD, Valentino AK, Freeman WD. Safety and efficacy of levetiracetam for critically ill patients with seizures. Neurocrit Care 2009;11:34-7.
16. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010;12:165-72.
17. Pellock JM, Glauser TA, Bebin EM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001;42:1574-9. (Pubitemid 34020096)
18. Glauser TA, Mitchell WG, Weinstock A, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007;48:1117-22. (Pubitemid 46854880)
19. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007;48:1351-9. (Pubitemid 47063068)
20. Gibaldi M, Perrier D. Pharmacokinetics. New York, NY: Marcel Dekker, 1982.
21. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumanii, Escherichia coli, and Klebsiella species collected from the United States intensive care units in 2004. Pharmacotherapy 2007;27:333-42.
22. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospitalacquired pneumonia. Clin Ther 2009;31:2765-78.
23. Naidech AM, Garg RK, Liebling S, et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke 2009;40:3810-15.
24. Fountain N. Should levetiracetam replace phenytoin for seizure prophylaxis after neurosurgery? Epilepsy Curr 2009;9:71-2.
25. Sahaya K, Goyal MK, Sarwal A, Singh NN. Levetiracetaminduced thrombocytopenia among inpatients: a retrospective study. Epilepsia 2010;51:2492-5.
26. Ramael S, De Smedt F, Toublanc N, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther 2006;28:734-44. (Pubitemid 44067259)
27. Uges JWF, van Juizen MD, Engelsman J, et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as addon in status epilepticus. Epilepsia 2009;50:415-21.